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Background: Age-related macular degeneration (AMD) is the leading cause of blindness among older adults in the
developed world. The only treatments currently available, such as ranibizumab injections, are for neovascular AMD,
which accounts for only 10 to 15% of people with the condition. Hypoxia has been implicated as one of the
primary causes of AMD, and is most acute at night when the retina is most metabolically active. By increasing light
levels at night, the metabolic requirements of the retina and hence the hypoxia will be considerably reduced. This
trial seeks to determine whether wearing a light mask that emits a dim, green light during the night can prevent
the progression of early AMD.
Methods/design: ALight is a Phase I/IIa, multicentre, randomized controlled trial. Sixty participants (55 to 88 years
old) with early AMD in one eye and neovascular AMD (nAMD) in the fellow eye will be recruited from nAMD
clinics. They will be randomized (in the ratio 1:1), either to receive the intervention or to be in the untreated control
group, stratified according to risk of disease progression. An additional 40 participants with healthy retinal
appearance, or early AMD only, will be recruited for a baseline cross-sectional analysis. The intervention is an eye
mask that emits a dim green light to illuminate the retina through closed eyelids at night. This is designed to
reduce the metabolic activity of the retina, thereby reducing the potential risk of hypoxia. Participants will wear the
mask every night for 12 months. Ophthalmologists carrying out monthly assessments will be masked to the
treatment group, but participants will be aware of their treatment group. The primary outcome measure is the
proportion of people who show disease progression during the trial period in the eye with early AMD. A
co-primary outcome measure is the rate of retinal adaptation. As this is a trial of a CE-marked device for an off-label
indication, a further main aim of this trial is to assess safety of the mask in the cohort of participants with AMD.
Trial registration: International Standard Randomised Controlled Trials Register: ISRCTN82148651
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Age-related macular degeneration (AMD) is the leading
cause of blindness in the developed world [1] and is re-
sponsible for more than 50% of visual impairment regis-
trations in the UK [2]. For the majority of people with
AMD, there is no treatment. The remaining 10 to 15%
of people with the advanced, neovascular, form of the* Correspondence: alison.binns.1@city.ac.uk
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article, unless otherwise stated.disease (nAMD) are mainly treated with intra-ocular in-
jections of ranibizumab, an anti-vascular endothelial
growth factor agent [3]. Follow-up treatment for these
patients is long-term and places a significant burden on
the UK National Health Service. Indeed, advanced AMD
currently costs the British economy £1.2 billion to £3.7
billion per annum [2,4,5]. Furthermore, the disease is as-
sociated with depression, falls and social isolation [6,7].
Given this significant socioeconomic problem, there is a
great need to evaluate potential therapeutic interven-
tions that attempt to treat the disease at an early stage,
to prevent vision loss from occurring.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the dysfunction and death of photoreceptors in the
central retina. There is an increasing amount of evi-
dence to suggest that hypoxia plays a major role in its
pathogenesis [8,9]. This has been attributed to various
factors, including a disruption of choroidal circulation
[10-13], and thickening and deposition of drusen at Bruch’s
membrane [9,14]. The latter increases the distance over
which oxygen must travel to reach the retinal pigment
epithelium from the choroidal circulation. Disease-related
changes to Bruch’s membrane also impair the diffusion
of nutrients and growth factors, which consequently ex-
acerbates choroidal perfusion abnormalities, promoting
further hypoxia [8,15].
Even in the healthy retina, intraretinal oxygen profiles
obtained from animals show that the oxygen tension at
the proximal side of the photoreceptor inner segments
is close to zero in darkness [16,17]. This is attributable
to the metabolic demand of the ‘dark current’ in the
retina’s approximately 120 million rods [18]. When this
limited supply of oxygen to the outer retina is further
compromised by the changes to the choroidal circula-
tion and Bruch’s membrane that occur in AMD, hyp-
oxia may result. This hypoxia could be the precursor
for increased vascular endothelial growth factor produc-
tion and apoptosis [19,20].
The fragile balance between metabolic demand and
oxygenation is exemplified functionally by the adverse
effects of hypoxia on colour vision [21-23], dark adapta-
tion [24,25], mesopic sensitivity [26] and the electroretino-
gram [12,27-29]. To date, there is no direct evidence of
the effect of hypoxia on visual function in AMD. However,
there is evidence that scotopic threshold elevation and
prolonged electroretinogram implicit times are associated
with areas of reduced choroidal blood flow in AMD
[30,31] and pilot data from our laboratory show a transi-
ent reduction in scotopic thresholds in an individual with
early AMD whilst inhaling oxygen.
Environmental manipulation of light levels can sub-
stantially reduce the metabolic demands on the outer
retina, thereby reducing the need for oxygen, and poten-
tially providing an intervention that would delay the
progression of conditions with a hypoxic aetiology [32].
A pilot study by Arden et al. [33] found no adverse effects
from the provision of low-level night lighting over the
course of 12 months in individuals with diabetic retinop-
athy [33]. Furthermore, a recent clinical trial in patients
with diabetic macular oedema who wore a low-level light
mask during the night for 6 months reported a reduction
in oedema and an improvement in functional measures,
which was attributed to the obviation of night-time hyp-
oxia [34]. In this trial, we will be using the same interven-
tion (low-level light therapy) to determine its ability to
prevent the development of AMD.Methods/design
Trial objectives
The primary aim of this study is to collect preliminary
Phase I/IIa proof-of-concept trial data from people with
early AMD in one eye and advanced nAMD in the fel-
low eye, recruited from a hospital nAMD clinic, in order
to assess the impact of low-level night-time light ther-
apy, compared with no intervention, on disease progres-
sion in the eye with early AMD. A further main aim of
this trial is to assess safety of the mask in the cohort of
participants with AMD.
The secondary aims of the study are to:
1. Establish the effect of low-level night-time light
therapy, compared with no-treatment control, on
secondary outcome measures, including: change in
drusen volume from baseline in the eye with early
AMD; ranibizumab retreatment rates in the fellow
eye with nAMD; progression of early AMD on the
basis of change in functional outcome measures;
change in health-related quality of life (assessed
using the EuroQol EQ-5D instrument); change in
self-reported visual function assessed using the
48-item Veterans Affairs Low-Vision Visual
Functioning Questionnaire (VA LV VFQ-48).
2. Establish the acceptability of low-level night-time
light therapy in people with AMD by monthly
qualitative interviews.
3. Determine the effect of low-level night-time light
therapy on sleep patterns by conducting the
Pittsburgh Sleep Quality Index (PSQI) questionnaire
every month with both intervention arms by
interview with the study investigator.
4. Establish the relationship between baseline
functional biomarker outcomes and the severity of
AMD (assessed using the simplified Age-Related Eye
Disease Scale (AREDS) and initial drusen volume).
5. Evaluate the ability of all clinical tests to act as
prognostic biomarkers for AMD progression.
6. Evaluate the ability of all clinical tests to act as
predictive biomarkers for low-level night-time light
therapy in people with AMD.
7. Compare the sensitivity of all clinical tests to disease
progression over 12 months.
Study design and setting
ALight is a Phase I/IIa prospective proof-of-concept
randomized controlled trial, consisting of two parallel
groups. Trial recruitment and data collection will take
place at the Medical Retina Clinic, Bristol Eye Hospital.
Additional cross-sectional data will be collected from
people with healthy eyes, or only early signs of AMD,
at the Cardiff University School of Optometry and
Vision Sciences.
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Inclusion criteria
 Between the ages of 55 and 88 years.
 Early Treatment of Diabetic Retinopathy Study
(ETDRS) visual acuity of 0.3 logMAR (Snellen 20/40
or 6/12) or better in the test eye.
 Early AMD in the study eye.
 nAMD in the fellow eye, within a month of the
third Ranibizumab injection (trial only).
 Willing to adhere to allocated treatment for
duration of trial.
Exclusion criteria
 Ocular pathology other than macular disease.
 Significant systemic disease or medication known to
affect visual function.
 Systemic disease that would compromise
participation in a 1-year study (trial only).
 Insufficient English language comprehension.
 Cognitive impairment as determined using an
abridged Mini Mental State Examination [7].
 Oxygen mask worn at night.
Suspension criteria for the trial
 Participant wishes to discontinue the study.
 Serious adverse events (for example, conversion to
nAMD in the test eye) or unexpected changes in
clinical status.
Interventions
Participants allocated to the treatment group will be
given a 12-weekly disposable light mask (Polyphotonix
Medical, UK) that presents organic light-emitting diode
illumination (peak output 502 nm) to both eyes, to be
used overnight for 12 weeks. Light masks will be replaced
every 12 weeks at the participant’s routine appointment at
the nAMD clinic so that the total duration of mask usage
is 12 months.
The mask provides a luminance of 75 photopic cd/m2.
When adjusted for the spectral sensitivity of rod photo-
receptors, this equates to 186 scotopic cd/m2 [35]. Light
transmission by the human eyelid has been found to
range between 0.3% and 2% for light in the region of
500 to 505 nm [36-38]. Under these conditions, the
pupil diameter in people in the age group 60 to 85 years
is approximately 4 mm [39]. This will result in a retinal
illuminance in the order of 23 scotopic Td (assuming
an eyelid transmission of 1%).
The masks will be pre-programmed to function only
between specific hours, that is, 8 pm to 8 am, to prevent
misuse. Outside of these hours, they will not illuminateif worn. The mask is activated when a touch sensor on the
device is gently covered with a finger for 3 seconds. It
will deactivate if not worn continuously for the first
15 minutes, and after that, the light will remain on for
the remainder of the 8-hour period.
Treatment acceptability will be evaluated during a
monthly interview with the study investigator. Compliance
data will be obtained at the monthly visit from the treat-
ment group both (i) through evaluation of a diary of mask
usage, and (ii) objectively through data collected on a chip
in the mask itself (based on a sensor which logs when the
mask is in contact with the face). This provides precise
data on the hours the mask is worn each night by each
participant. As each mask is programmed with the unique
participant identification code, compliance data stored
on-chip will be non-identifiable except via the password-
protected electronic database.
The current management of patients with early AMD
involves advising on lifestyle factors, such as stopping
smoking and improving diet. The only other interven-
tion that is based on evidence from a robust randomized
controlled trial is the provision of a nutritional supplement
consisting of high-dose antioxidants plus zinc. This AREDS
group formula (vitamin C, 500 mg; vitamin E, 400 IU;
beta carotene, 15 mg and zinc, 80 mg) has been shown
to reduce risk of progression from early to advanced
AMD by around 20% over 5 years in people with spe-
cific features of AMD [40]. However, a recent systematic
review by the Cochrane Collaboration indicated that
there may be an increased risk of mortality in individuals
taking vitamin E and beta carotene supplementation [41].
As this is a recently published document, its advice is not
reflected in the current guidelines for the management of
AMD. For this reason, the low-level light therapy will be
compared with a no-treatment control, rather than with
the AREDS group formula as the best current intervention.
Participants in both groups will receive routine ophthal-
mological care for the eye with nAMD (that is, ranibizumab
injections). If the eye with early AMD converts to nAMD,
the participant will proceed to ranibizumab treatment for
this eye also, and will be withdrawn from the study.
Outcome measures
This study includes two co-primary outcome measures,
reflecting structural status and functional status.
1. The proportion of people who show ‘disease
progression’ in the eye with early AMD during the
12 months of the study based on an increase in
drusen volume beyond test-retest repeatability limits
or a progression to advanced AMD. Software available
for the Cirrus optical coherence tomography
(OCT) system allows automated assessment of
drusen volume. Irrespective of initial drusen
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show a significant increase in drusen volume over
the 12-month study period, that is, beyond test-retest
95% confidence intervals [42]. Conversion to
advanced disease will also be considered to be an
indicator of disease progression in this analysis. Data
from a trial on a similar group indicates that about
10% of people meeting our inclusion criteria will
develop advanced AMD within 12 months [43].
Hence, 60% of participants might be expected to show
progression based on increased drusen volume or
progression to late AMD. The development of
advanced AMD will be determined on the basis of
ophthalmologist diagnosis at the monthly
follow-up appointments at the nAMD clinic.
2. The rate of retinal adaptation (time taken for
photoreceptors to recover their sensitivity after
being exposed to a bright adapting light).
Secondary outcome measures include: the change in
drusen volume over the 12 month follow-up period; the
number of ranibizumab retreatments required during
the year in the fellow eye with nAMD (assessed through
review of medical records at the end of 12 months);
changes in visual function including chromatic thresholds,
visual acuity and psychophysical 14 Hz flicker thresholds;
self-report outcome measures, including health-related
quality of life (EQ-5D) and visual function (VFQ-48) [44];
a sleep quality questionnaire (PSQI) and a semistructured
interview (conducted monthly by interview) to determine
intervention acceptability.
To obtain detailed information about the time course of
any therapeutic action, the primary and the first of the
secondary outcome measures (based on drusen volume)
will be assessed at baseline and then at monthly intervals
(using OCT images obtained at the regular nAMD clinic
follow-up appointments).
Participant timeline
The study flow diagram (Figure 1) outlines the appoint-
ment schedule. In brief, potential participants are identi-
fied at their first visit to the nAMD clinic. At the second
visit (1 month later), informed consent will be obtained,
and screening tests and baseline questionnaires will be
carried out. At the third monthly visit, baseline func-
tional tests will be carried out, and participants will be
randomly assigned to either the treatment or interven-
tion group. Participants in both intervention groups
will attend a short, monthly follow-up appointment
following their routine appointment at the nAMD
clinic throughout the year. Final outcome data will be
collected from control and intervention groups at a
12-month follow-up appointment, scheduled to follow
a regular visit to the nAMD clinic.Participants in the cross-sectional baseline study will
attend Cardiff University or the Bristol Eye Hospital for
one visit only.
Recruitment
Sixty participants will be recruited to the trial. Ophthal-
mologists will identify potential trial participants who
are attending for their first appointment at the nAMD
clinic at Bristol Eye Hospital, and will provide them with
an information sheet and ask for their permission to be
contacted by the study investigators. The potential par-
ticipants will be contacted at least 2 days after their
receipt of the information sheet, and invited to meet the
study investigator at their next visit to the nAMD clinic
(approximately 1 month later) to discuss the trial, pro-
vide consent if they choose to participate, and carry out
some basic screening tests. Participants will be informed
after this screening visit whether they are eligible to take
part in the study. Owing to the low number of patients
required to participate in the study it is planned for the
trial and data collection to take place principally at a single
NHS centre, that is, the Bristol Eye Hospital. If needed,
additional participants will be recruited from supplemen-
tary recruitment centres to ensure that targets are met.
Forty control participants and participants with grade
1 AMD (AREDS simplified scale [45]) for the baseline
cross-sectional analysis will be recruited by local optom-
etrists in Bristol and Cardiff, from a database of elderly
volunteers, from the Bristol Eye Hospital, from the list of
research volunteers at the Cardiff University Eye Clinic
and from staff and students of Cardiff University.
Randomization
Participants will be stratified according to risk of AMD
progression (using the AREDS simplified scale [45]), and
randomly allocated to receive either the light mask or no
intervention in a 1:1 ratio using computer-generated
random permuted blocks (both groups will continue to re-
ceive ranibizumab injections as required for the fellow eye).
The study investigator will be provided with three piles of
envelopes by the chief investigator, in order to randomize
the participant to either the intervention or control arm
of the study. Each pile relates to a different stratum of
randomization, that is, grade 2, 3 or 4 of AMD, according
to the AREDS simplified scale. The envelopes in each pile
will be numbered, and will contain the randomization
allocation for each participant.
Masking
It is not appropriate in this study to use a sham treatment,
since a non-illuminated mask may have a physiological
effect on the retina and patients would be aware that
they weren’t perceiving light and so would be unmasked
to their intervention group. The study investigator who
Figure 1 Study flow diagram showing participant timeline.
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masks and instructions on its usage and, hence, will not be
masked to the intervention group. However, the potential
for experimenter bias is limited, as the primary outcome
measure, disease progression, is an objective measurement
carried out by automated computer software. The ophthal-
mologists who are seeing the participants for their regular
ranibizumab injections will be masked, which will prevent
any bias in their retreatment decisions for the fellow eye.
Data collection methods
Screening visit
Following a discussion of the study, and the obtaining
of informed consent, the study investigator will question
the participant regarding ocular and medical history.
Retinal photographs will be taken if they have not already
been acquired, and repeated if image quality is insufficient
to allow evaluation. The OCT and fundus photographswill be assessed to check for eligibility. The Van Herick
angle of drainage will be measured, media clarity will be
assessed for each eye and the lens graded according to the
Lens Opacities Classification System III grading scale [46].
Visual acuity will be assessed in each eye using the ETDRS
chart, following a brief refraction, if necessary. An abridged
version of the Mini Mental State Examination will be used
to assess for cognitive impairment (5 min; [7]).
Those still deemed eligible for inclusion in the study will
also complete several questionnaires, through verbal inter-
view with the investigator: visual function (VA LV VFQ-48)
[44]; health-related quality of life (EQ-5D); sleep quality
(PSQI) [47]; smoking history (pack years); vitamin sup-
plementation; ethnic origin.
Baseline assessment
Optical coherence tomography images and fundus pho-
tographs obtained during the participant’s routine visit
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assess drusen volume and AMD grade, according to the
AREDS simplified scale [45]. If the images are of insuffi-
cient quality, additional images will be captured.
The ETDRS visual acuity will be assessed in each eye.
Chromatic thresholds will be measured for the eye with
early AMD using the Colour Assessment and Diagnosis
test [48] (City Occupational Ltd). Contrast thresholds to a
14 Hz flickering stimulus will be measured for the eye with
early AMD using the procedure outlined by Dimitrov et al.
[49]. The rate of parafoveal cone dark adaptation will be
determined for the eye with early AMD using a psycho-
physical procedure described previously [50]. Thresholds
will be determined using a psychophysical method, based
on a ‘3 down, 1 up’ staircase paradigm [50]. An array of
white light-emitting diodes behind a diffusing filter will
be used to light-adapt photoreceptors in the central 43.6° of
the test eye (the output of the white light-emitting diodes
will be modified by a Lee filter, HT015, to provide a retinal
illuminance of 5.20 log phot Td.s−1, providing a bleach of
85% cone photopigment and 74% rhodopsin). All light
levels fall within the safety guidelines set out in British
Standard BS EN 15004-2 (2007) [51]. There will be an
initial training phase, of around 5 minutes, then the
adapting light will be presented, and finally recovery of
visual thresholds will be monitored for 25 minutes after
exposure to the adapting light.
Those individuals who are assigned to the treatment
group will then be given a light mask, and provided with
written and oral instructions on its use. There will also
be a reprise of the key information provided in the par-
ticipant information letter about follow-up appoint-
ments. Participants will be given written copies to take
home of the PSQI questionnaire that will be used in
the monthly interview.
Monthly assessment
The investigator will access the OCT images and medical
records of all participants after they have attended the rani-
bizumab clinic for each monthly follow-up appointment.
This will allow measurement of drusen volume on a
monthly basis, which will allow the final analysis to include
an assessment of the time course of any therapeutic action.
Additionally, reviewing medical records will facilitate moni-
toring of the conversion rate to advanced AMD in the con-
trol and intervention groups in the eye with early AMD at
baseline, and of ranibizumab retreatment rates in the eye
with nAMD, for adverse event reporting purposes.
Participants in both intervention groups will attend a
short, monthly follow-up appointment following their
routine ranibizumab clinic appointment, during which
both groups will complete the PSQI sleep quality question-
naire. In addition, the treatment group will bring their mask
along to each monthly visit to allow objective compliancedata (nightly hours of use) to be exported from the device,
retraining in mask use if required, functionality of the mask
to be checked, masks to be replaced every 12 weeks, and a
semistructured interview to be carried out to determine the
acceptability of the intervention. These data will be used to
address secondary objectives 2 and 3.
Final (12-month) visit
This visit will be the same as the baseline visit with the
addition of a final semistructured interview assessing the
acceptability of the intervention, and the questionnaires
(PSQI, VA LV VFQ-48, Euroqol).
Baseline cross-sectional study
The 40 participants recruited only to the cross-sectional
part of the study will undergo the tests outlined in the
baseline assessment visit of the trial.
Statistical methods
It should be noted that, as a Phase I/IIa proof-of-concept
study, this research is designed to assess the acceptability
of this therapy for the participants, and to provide prelim-
inary data to support a larger Phase III randomized con-
trolled trial in the future, and so is not powered to detect
small effect sizes. To maximize retention, all follow-up
visits will be timed to coincide with scheduled appoint-
ments at the nAMD clinic. We will aim to recruit 60
people, which, allowing for 15% dropout through the year,
should leave a final cohort of 51. This will be sufficient to
detect a 50% reduction in people showing progression at a
probability level of 0.2, with a power of 80%, and a change
in the time constant of cone adaptation of 1 minute to be
detected at a probability level of 0.05, with a power of
80%. The additional 40 participants enrolled into the
cross-sectional part of the study will allow a total cohort
of n = 100 to address secondary aim 4.
Analysis will be carried out on an intention-to-treat
basis. There will be no interim analysis, but conversions
to nAMD in the eye with early AMD at baseline, and
ranibizumab retreatments for the fellow eye, will be re-
corded at each participant visit to the nAMD clinic for
safety monitoring purposes.
This trial will primarily be concerned with providing
information about the safety of the device in the treatment
of AMD, and the magnitude of any treatment effect.
On this basis, descriptive statistics will be carried out
to summarize the demographic characteristics of the
two groups, as well as the proportion of individuals
showing disease progression in each group, the magnitude
of changes in secondary outcome measures, including
drusen volume, measures of visual function, and the
self-report tests, and the fellow eye retreatment rates.
The primary outcome measure will be the proportion of
patients demonstrating disease progression at 12 months.
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Haenszel tests and presented as forest plots.
Formal statistical analysis will also include linear
regression analysis to investigate changes in drusen
volume controlling for intervention arm, baseline drusen
volume and patient characteristics (such as age, vitamin
supplement intake and history of smoking). Analysis of
covariance (ANCOVA) will be carried out to compare
the change in secondary outcome measures (for example,
drusen volume, functional tests, self-report measures)
and the ranibizumab retreatment rates over 12 months
between the two intervention arms, controlling for the
characteristics listed previously. Note that all analysis
except for the ranibizumab retreatment rate pertains
to the eye with early AMD. This will address secondary
aim 1. To meet our fourth secondary aim, which is to
establish the relationship between baseline functional
biomarker outcomes and the severity of AMD, we will
carry out a one-way analysis of variance (ANOVA) to
compare the mean results at baseline between partici-
pants with grades of AMD in each group on the AREDS
simplified scale. This analysis will take place when the
baseline data collection is complete. To assess the
ability of the clinical tests to act as prognostic and
predictive biomarkers, receiver operating characteris-
tics curves will be constructed to plot the sensitivity
and specificity of the baseline measures in predicting
outcomes within the control and intervention arms, re-
spectively. This will address secondary aims 5 and 6.
When the trial is completed, linear regression analysis
will be used to determine how well the change in the
functional measures relate to the change in our primary
outcome measure (drusen volume), which is a validated
biomarker for disease progression. This will address the
seventh secondary aim.
Trial management
The chief investigator has ultimate responsibility for
the trial management, assisted by the trial manage-
ment group. Any important protocol modifications
will be communicated to all relevant parties (investi-
gators, research ethics committee, NIHR CRN Portfolio,
trial registry, journals, NHS Research and Develop-
ment, device manufacturer, funding body) by the chief
investigator.
A trial steering committee has been established, which
will also act as a data monitoring committee. In addition
to annual meetings, the committee will be issued with
information about any adverse events throughout the
course of the study, so that they can decide whether it is
appropriate for the study to be terminated. A 3-monthly
newsletter will be issued to all investigators and the
steering committee, updating on recruitment and other
issues, throughout the trial.Safety monitoring
All adverse events (AEs) and serious adverse events
(SAEs) will be recorded. The chief investigator (AB) will
be provided with an update of AEs every month and all
SAEs within two working days. This trial does not in-
volve a medicinal product or life-threatening procedure.
Hence, the risk of a SAE is low. However, one potential
SAE is an increased rate of progression to nAMD in the
eye with early AMD at baseline. Although this is at
odds with the literature, it is not an impossible out-
come. Another potential SAE would be an increased
rate of recurrence of nAMD in the fellow eye (resulting
in increased ranibizumab retreatment rates). Conversion to
nAMD and Ranibizumab retreatment requirement in the
fellow eye will be determined by ophthalmologists at the
monthly ranibizumab clinic, and recorded by the study in-
vestigator through assessment of medical records after each
monthly ranibizumab appointment.
Wong et al. [52] carried out a meta-analysis of studies,
which had looked at the progression to choroidal neovascu-
larization in the fellow eye when free of advanced disease at
study inception. They reported that the cumulative 1-year
incidence of nAMD in the 426 patients enrolled in the five
studies that evaluated this outcome was 12.2% (confidence
interval, 1.7% to 30.6%). Therefore, we have placed an
upper limit on the number of people expected to convert
to nAMD per month of n × (30.6% / 12 months), where n
is the number of people in the trial who are using the light
therapy light mask.
The chief investigator will assess the nature of the AEs
and SAEs for seriousness, causality and expectedness.
Following the initial report, follow-up data may be re-
quested by the chief investigator. Where the SAE is both
related and unexpected, the chief investigator will no-
tify the Trial Steering Committee, the trial sponsor, the
National Research Ethics Service North West, and the
device manufacturer, who will notify the Medicines
and Healthcare Regulatory Agency within 15 days of
receiving notification of the SAE.
Data management
Any trial data will be recorded on spreadsheets using
the numerical identifier for each patient. These data
will be non-identifiable. All paper records will also use
the unique numerical identifier, which will be non-
identifiable. The only identifiable personal data will be
the paper and electronic copies of the patient database.
The paper copy will not be transferred between Cardiff
University and the Bristol Eye Hospital, and will be
kept in a locked filing cabinet at all times. The electronic
database will be stored on a secure Cardiff University
computer drive, which is accessible from Bristol and
Cardiff via a password-protected connection. The study
database will be checked for integrity every month by
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belong to Cardiff University. At this time, Polyphotonix
Medical Ltd (the manufacturer) will have access to the
results. Anonymized data will be available for verification at
any time by the funding body, the College of Optometrists,
on request. Neither the College of Optometrists, nor
Polyphotonix Medical Ltd. will influence the data collec-
tion or analysis. All data will be kept for 15 years, in line
with Cardiff University’s Research Governance Framework
Regulations for clinical research.
Dissemination
A summary of the trial protocol is available to the public
through the International Standard Randomised Controlled
Trials Register. Any interested individuals may contact
the chief investigator for further information. Results will
be published in peer-reviewed journals and at International
Conferences. The chief investigator has ultimate re-
sponsibility for the scientific content of any publica-
tions. Dissemination of results to trial participants will
take place through a summary-of-findings newsletter sent
at the end of the trial to those individuals who indicate a
desire to receive an update. Dissemination to the wider
community of people with AMD will take place through
publication in the Macular Society’s members’ magazine,
Digest, and through presentations at such events as the
Macular Society ‘Top Doctors’ conference. Neither the
funding body (the College of Optometrists), the light mask
manufacturer (Polyphotonix Medical Ltd), nor the spon-
sor (Cardiff University) will influence the presentation or
the publication of the research.
Ethical considerations
The study has been approved by the National Research
Ethics Service North West, and is registered with the
International Standard Randomised Clinical Trials Register.
A notice of no objection has been obtained from the
Medicines and Healthcare Regulatory Agency. The trial
will be conducted in adherence with the Declaration of
Helsinki and the Good Clinical Practice guidelines. The
chief investigator and the research team will preserve
the confidentiality of participants in accordance with
the Data Protection Act 1998.
Audits and inspections
The trial is liable to inspection by the College of
Optometrists as the funding organization. The study
may also be liable to inspection and audit by Cardiff
University under their remit as sponsor.
Discussion
In this article, we present a clinical trial protocol to
evaluate the effect of low-level night-time light therapy
in patients with early AMD. To our knowledge, this isthe first randomized controlled trial of its kind in AMD.
This study will provide the foundation for future large-scale
clinical trials. With the prediction of longer life expectancy
in the future, the prevalence of AMD and its associated so-
cial and economic problems will continue to increase un-
less a treatment is developed that will stop its progression.
Trial status
This protocol aims to establish the therapeutic benefit of
low-level light therapy on disease progression in AMD.
Recruitment will begin in April 2014 and continue until
February 2015. Data collection will take place from June
2014 to April 2016.
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